PolTREG SA develops and commercializes patented TREG methods. It engages in the research, development, implementation, and commercialization of T-regulatory lymphocytes and using their growth method for clinical use to treat type 1 diabetes. The company was founded in 2015 by Piotr Trzonkowski, Malgorzata Mysliwiec, Wojciech Tadeusz Kakol and Natalia Maria Marek Trzonkowska and is headquartered in Gdansk, Poland.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company